Use of almitrine in spontaneously breathing patients with COVID-19 treated with high-flow nasal cannula oxygen therapy and with persistent hypoxemia.

ABSTRACT:

Background

Almitrine, a selective pulmonary vasoconstrictor in hypoxic area, improves oxygenation in mechanically ventilated patients with COVID-19 but its effects in spontaneously breathing patients with COVID-19 remain to be determined.

Methods

We prospectively studied the effects of almitrine (16 µg/kg/min over 30 min followed by continuous administration in responders only) in 62 patients (66% of male, 63 [53-69] years old) with COVID-19 treated with high-flow nasal cannula oxygen therapy (HFNO) and with persistent hypoxemia, defined as a PaO₂/FiO₂ ratio < 100 with FiO₂ > 80% after a single awake prone positioning session. Patients with an increase in PaO₂/FiO₂ ratio > 20% were considered as responders.

Results

SUBMITTER: Saccheri C 

PROVIDER: S-EPMC9812745 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature